

Ravi Savarirayan, M.B.B.S., F.R.A.C.P., H.G.S.A., MD
Clinical Geneticist

Murdoch Children's Research Institute
Royal Children's Hospital

Professor Ravi Savarirayan is a clinical geneticist and Group Leader of Skeletal Biology and Disease at Murdoch Childrens Research Institute. He is also Head of Clinical Genetics Services at the Victorian Clinical Genetic Services.

Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Group leader (Musculoskeletal research) at Murdoch Children's Research Institute, Victoria, Australia.

Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998, and was awarded his Doctorate of Medicine from the University of Melbourne in 2004, for his thesis "Clinical and molecular studies in the Osteochondrodysplasias." He was the youngest recipient of the Fulbright Professional Scholarship for Australia in 1998, and took his fellowship up at University of California, Los Angeles (UCLA).

Professor Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium and is the current Chair of the Advanced Training Committee in Clinical Genetics, Royal Australasian College of Physicians. He was the first Australian elected President of the International Skeletal Dysplasia Society, and has been invited to give plenary talks at major scientific conferences in North and South America, Asia, Europe, the Middle East and Australasia.

Professor Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 170 peer-reviewed articles, collaborating with researchers from over 40 countries. He serves on the editorial boards several scientific journals, including *Human Mutation*, *European Journal of Human Genetics*, *American Journal of Medical Genetics*, and *Journal of Medical Genetics*.

His current clinical trial activities are pioneering disruptive new therapies for the treatment of inherited bone disorders, and he is a passionate advocate for equal access and uptake of these new genetic technologies and therapies.

For more information about Dr. Savarirayan, including a full list of his publications, please visit his [institution website](#).